FindTrial
Sign In

Trepilimumab in perioperative treatment of non-small cell lung cancer: a prospective, observational, multi-center, real-world study

Trepilimumab in perioperative treatment of non-small cell lung cancer: a prospective, observational, multi-center, real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091457
Enrollment
Unknown
Registered
2024-10-29
Start date
2024-10-30
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Different subgroups:None

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Voluntarily participate and sign an informed consent form; 2.Stage II-III NSCLC diagnosed by histology or pathology; 3.Intending to receive perioperative treatment with Trepilimumab; 4.According to RECIST 1.1 assessment, there are measurable lesions.

Exclusion criteria

Exclusion criteria: 1. Individuals known to be allergic to recombinant humanized anti-PD-1 monoclonal antibody drugs and their components; 2. Researchers determine other situations that are not suitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
EFS;—

Secondary

MeasureTime frame
Efficacy measures (pCR rate, MPR rate, ORR, DFS, OS);—

Countries

China

Contacts

Public ContactChang Chen

Shanghai Pulmonary Hospital

changchenc@tongji.edu.cn+86 21 6511 5006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 29, 2026